Veloxis Pharmaceuticals' $46 Million Reckoning: Inside the Kickback Scandal Rocking a Transplant-Drug Maker

The Big One: A $46 Million Admission of Guilt

Veloxis Pharmaceuticals is now facing the most damaging chapter in its corporate history. On August 10, the U.S. Department of Justice announced that the transplant-drug maker agreed to pay $46 million to resolve criminal and civil liability stemming from a kickback scheme tied to its flagship product, Envarsus XR. This is not a case of alleged wrongdoing quietly settled to make headlines go away — Veloxis admitted to illegal conduct. According to DOJ, the company paid kickbacks to healthcare professionals and specialty pharmacies specifically to induce prescriptions of Envarsus XR, a scheme structured to look like legitimate business activity while functioning as a pay-to-prescribe arrangement.

The financial breakdown is stark: a $10 million criminal penalty, a deferred prosecution agreement that keeps the company under federal supervision, and a $36 million civil settlement under the False Claims Act. A deferred prosecution agreement is a serious instrument — it means Veloxis avoided a formal criminal conviction only by agreeing to strict compliance conditions and admitting to the underlying facts. For a pharmaceutical company whose business depends on trust from physicians, hospitals, insurers, and patients, this is about as close to a worst-case regulatory outcome as exists short of exclusion from federal healthcare programs.

The Whistleblower Who Blew It Open

This settlement didn't happen in a vacuum — it was the product of a qui tam whistleblower lawsuit. Just five days after the DOJ announcement, a report via AOL detailed how the law firms Kleiman Rajaram and Phillips & Cohen successfully prosecuted the False Claims Act case that exposed Veloxis's scheme. The whistleblower complaint reportedly detailed concealed payoffs that violated the Open Payments Program, better known as the Sunshine Act — the federal transparency law specifically designed to force disclosure of financial relationships between drugmakers and prescribers.

The irony is pointed: a law built to shine light on industry payments was allegedly circumvented by Veloxis in order to keep its kickback arrangements hidden from regulators and the public. That a whistleblower — likely a former employee or business partner with inside knowledge — had to step forward to trigger a federal investigation speaks to how deeply embedded the conduct may have been. Qui tam cases of this size also tend to generate a second wave of press coverage months and years later, as plaintiff's firms tout the win and use it as a template for soliciting future whistleblowers against the company or its peers. Veloxis should expect this story to have a long tail.

Patent Litigation Adds to the Legal Noise

While the kickback scandal dominates the headlines, Veloxis has also been managing separate intellectual property litigation. PatSnap's litigation analysis documents a patent dispute between Veloxis and Sun Pharmaceutical Industries over tacrolimus extended-release formulations — the same drug class at the heart of Envarsus XR. A consent judgment and injunction were entered in the case, a relatively routine outcome in pharma patent litigation and, on its own, not damaging. But layered on top of an active federal kickback investigation, even routine litigation starts to read differently to journalists, competitors, and institutional investors scanning the news for red flags. Litigation clusters compound reputational risk — every new court filing becomes another data point that gets folded into the

Sources

1. U.S. Department of Justice — Veloxis Pharmaceuticals Agrees to Pay $46 Million to Resolve Criminal and Civil Liability for Kickback Scheme
2. AOL — Kleiman Rajaram and Phillips & Cohen Announce Successful $46 Million Qui Tam Action Against Veloxis Pharmaceuticals
3. PatSnap — Veloxis v. Sun Pharma: Tacrolimus Patent Consent Judgment | PatSnap

Disclaimer: The information presented in this article was published by third parties and is aggregated here for research and commentary purposes only. NegativePublicRelations.com does not claim these allegations as fact; all claims are attributed to their original publishers, linked above. Readers are encouraged to review the original sources. This post is not legal advice.